Myoclonus refers to a sudden, involuntary jerking of a muscle or group of muscles. In its simplest form, myoclonus consists of a muscle twitch followed by relaxation. A hiccup is an example of this type of myoclonus. Other familiar examples of myoclonus are the jerks or "sleep starts" that some people experience while drifting off to sleep. These simple forms of myoclonus occur in normal, healthy persons and cause no difficulties. When more widespread, myoclonus may involve persistent, shock-like contractions in a group of muscles. Myoclonic jerking may develop in people with multiple sclerosis, Parkinson's disease, Alzheimer's disease, or Creutzfeldt-Jakob disease. Myoclonic jerks commonly occur in persons with epilepsy, a disorder in which the electrical activity in the brain becomes disordered and leads to seizures.
Treatment of myoclonus focuses on medications that may help reduce symptoms. The drug of first choice is clonazepam, a type
of tranquilizer. Many of the drugs used for myoclonus, such as barbiturates, phenytoin, and primidone, are also used to treat
epilepsy. Sodium valproate is an alternative therapy for myoclonus and can be used either alone or in combination with clonazepam.
Myoclonus may require the use of multiple drugs for effective treatment.
Simple forms of myoclonus occur in normal, healthy persons and cause no difficulties. In some cases, myoclonus begins in one
region of the body and spreads to muscles in other areas. More severe cases of myoclonus can distort movement and severely
limit a person's ability to eat, talk, or walk. These types of myoclonus may indicate an underlying disorder in the brain
or nerves. Although clonazepam and sodium valproate are effective in the majority of people with myoclonus, some people have
adverse reactions to these drugs. The beneficial effects of clonazepam may diminish over time if the individual develops
a tolerance for the drug.
The National Institute of Neurological Disorders and Stroke (NINDS) conducts research relating to myoclonus in its laboratories
at the National Institutes of Health (NIH) and also supports additional research through grants to major medical institutions
across the country. Scientists are seeking to understand the underlying biochemical basis of involuntary movements and to find the most effective
treatment for myoclonus and other movement disorders. Researchers may be able to develop drug treatments that target specific biochemical changes involved in myoclonus. By combining several of these drugs, scientists hope to achieve greater control of myoclonic symptoms.
WE MOVE (Worldwide Education & Awareness for Movement Disorders) 204 West 84th Street New York, NY 10024 wemove@wemove.org http://www.wemove.org Tel: 212-875-8312 Fax: 212-875-8389 |
National Organization for Rare Disorders (NORD) P.O. Box 1968 (55 Kenosia Avenue) Danbury, CT 06813-1968 orphan@rarediseases.org http://www.rarediseases.org Tel: 203-744-0100 Voice Mail 800-999-NORD (6673) Fax: 203-798-2291 |
Prepared by:
Office of Communications and Public Liaison
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD 20892
NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history.
All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated.
Last updated December 11, 2007